Navigation Links
Dendreon Announces Webcast Presentation at Upcoming Conferences
Date:5/20/2011

SEATTLE, May 20, 2011 /PRNewswire/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that management will present at the following conferences:

  • ThinkEquity Annual Healthcare Conference in New York City, NY on May 25, 2011 at 1:00 p.m. ET
  • Goldman Sachs Annual Global Healthcare Conference in Rancho Palos Verdes, CA on June 7, 2011 at 2:00 p.m. PT

The presentations will be webcast live and available for replay from Dendreon's website, www.dendreon.com.  If you are unable to listen to the live webcasts, they will be archived on the site following the presentation. To access the replay, go to the Investor Relations section of the website.

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development, commercialization and manufacturing of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response in a variety of tumor types. Dendreon's first product, PROVENGE®, was approved by the FDA in April 2010. Dendreon is exploring the application of additional ACI product candidates and small molecules for the potential treatment of a variety of cancers. The Company is headquartered in Seattle, Washington and is traded on the NASDAQ Global Market under the symbol DNDN. For more information about the Company and its programs, visit http://www.dendreon.com/.


'/>"/>
SOURCE Dendreon Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Dendreon Reports First Quarter 2011 Financial Results
2. Dendreon to Host Conference Call on May 2, 2011 to Announce First Quarter 2011 Financial Results
3. Dendreon Reports Fourth Quarter and 2010 Year End Financial Results
4. Dendreon Announces Webcast Presentations at Four Upcoming Conferences
5. Dendreon Announces Presentation of PROVENGE Data at the 2011 Genitourinary Cancers Symposium Annual Meeting
6. Dendreon to Host Conference Call on March 1st to Announce Fourth Quarter and Year-End Financial Results
7. Dendreon Announces Pricing of $540 Million Convertible Senior Notes Due 2016
8. Dendreon Announces Plans to Seek Marketing Authorization for PROVENGE in Europe
9. Dendreon to Host Conference Call to Provide Updates on U.S. Commercialization Progress, European Strategy for PROVENGE, and Pipeline Progress
10. Dendreon Announces MEDCAC Panel Reviewed PROVENGE Evidence
11. Dendreon Submits Post-Approval Supplement to the PROVENGE Biologics License Application for New Jersey Manufacturing Facility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , ... December 08, 2016 ... ... the commercial launch of flexible packaging for their exceptionally efficient human mesenchymal ... system extends RoosterBio’s portfolio of bioprocess media products engineered to radically streamline ...
(Date:12/8/2016)... 2016  Soligenix, Inc. (OTCQB: SNGX) (Soligenix or ... developing and commercializing products to treat rare diseases ... today the long-term follow-up data from its Phase ... Innate Defense Regulator (IDR), in the treatment of ... patients undergoing chemoradiation therapy (CRT).  The additional 12-month ...
(Date:12/8/2016)... Savannah River Remediation LLC group evaluated ... NT-MAX Lake & Pond Sludge and Muck ... conjunction with Hexa Armor/ Rhombo cover manufactured by ... Discharge Elimination System requirements. The Savannah ... of elevated pH levels, above 8.5, especially during ...
(Date:12/8/2016)... 2016   Biocept, Inc . (NASDAQ: ... clinically actionable liquid biopsy tests to improve the ... featuring its Target Selectorâ„¢ Circulating Tumor Cell platform ... detection of actionable biomarkers in patients with metastatic ... Sara Cannon Research Institute (SCRI), the research arm ...
Breaking Biology Technology:
(Date:12/2/2016)... 2016   SoftServe , a global digital ... an electrocardiogram (ECG) biosensor analysis system for continuous ... asset. The smart system ensures device-to-device communication between ... and mobile devices to easily ,recognize, and monitor ... vehicle technology advances, so too must the security ...
(Date:11/29/2016)... 29, 2016   Neurotechnology , a ... recognition technologies, today released FingerCell 3.0, a ... solutions that run on low-power, low-memory microcontrollers. ... less than 128KB of memory, enabling it ... have limited on-board resources, such as: mobile ...
(Date:11/22/2016)... India , November 22, 2016 According to ... (Fingerprint, IRIS, Palm Print, Face, Vein, Signature, Voice), Multi-Factor), Component (Hardware and ... 2022", published by MarketsandMarkets, the market is expected to grow from USD ... a CAGR of 16.79% between 2016 and 2022. ... ...
Breaking Biology News(10 mins):